A single residue contributes sensitivity to allosteric modulation of AMPA receptors by LY395153.
Previous studies have shown that a single point mutation (S(750)Q) in the splice variant region of rat Glu(1) subunits can eliminate positive allosteric modulation by cyclothiazide. The present study investigated the effects of mutating the equivalent residue (S(776)Q) in the human Glu(4) subunit on the activity and binding of a novel AMPA receptor potentiator, LY395153 (N-2-(4-benzamidophenylpropyl-2-propanesulfonamide)). The mutation markedly attenuated, but did not eliminate, potentiation by LY395153 and cyclothiazide. In addition, binding of [3H]LY395153 was significantly reduced by this mutation. These effects occurred in the absence of any change in the response to glutamate or the binding of a competitive AMPA receptor antagonist, [3H]Ro 48-8587 ([2,4,5-3H]9-imidazol-1-yl-8-nitro-2,3,5,6-tetrahydro[1,2,4]-triazolo[1,5-c]quinazoline-2,5-dione triethylammonium salt). Collectively, these results demonstrate that structurally diverse classes of potentiators are sensitive to mutations of this single Ser residue, suggesting that binding to this residue may be necessary for positive allosteric modulation of AMPA receptors.
Quirk
Jennifer C
JC
Neuroscience Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285-0510, USA.
Linden
Anni-Maija
AM
Strakhova
Marina
M
Yu
Hong
H
Skolnick
Phil
P
Nisenbaum
Eric S
ES
D000494:Allosteric Regulation / Q000187:drug effects / Q000502:physiology; D001549:Benzamides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D006801:Humans; D017354:Point Mutation / Q000187:drug effects / Q000502:physiology*; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D018091:Receptors, AMPA / Q000819:agonists / Q000235:genetics* / Q000378:metabolism*; D013449:Sulfonamides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology
D001549:Benzamides; C434044:N-2-(4-benzamidophenylpropyl-2-propanesulfonamide); D018091:Receptors, AMPA; D013449:Sulfonamides